Bead Assay to Select Effector Cells Against Cancer, HIV, or Other Diseases
The Weitz Lab has developed a bead assay that enables the detection of single cell cytokine secretion which is impossible by traditional well-plate methods, and a method that incorporates the bead assay with microfluidics to first identify effector cells against various diseases/antigens with a near 100% accuracy and then select these highly specialized effector cells at a >90% avidity rate (the ratio of effector cells in a selected population), in a total time period of less than 12 hours. This method not only significantly improves the efficiency and efficacy of adoptive cell therapy, but also enables the study of various types of single-cell responses, which is important to the whole biotechnology and biomedical community.
This method employs the microfluidic technologies previous developed in the Harvard laboratory of Prof. David A. Weitz.
Intellectual Property Status: Patent(s) Pending